ReviewBMJ oncology2023
Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps.
Review in BMJ oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Benefits and Harms of Screening for Prostate Cancer in Adults Aged 18 Years and Older: A Systematic Review.Current oncology (Toronto, Ont.) · 2026Pooled it
- A Bayesian bivariate spatial modeling framework for stage-specific cancer incidence and targeting of screening efforts.American journal of epidemiology · 2026Article
- Ongoing and completed clinical trials on prostate cancer screening using MRI.European radiology · 2026Review
- The performance of prostate-specific antigen density in long-term prostate cancer-mortality risk prediction.BJUI compass · 2026Article
- Prostate-specific antigen testing and prostate cancer-related outcomes: a Danish nationwide study.BJU international · 2026Article
- Integrative advances in biomarker-driven prostate cancer management from genomic discovery to precision oncology.Discover oncology · 2026Review
- Artificial intelligence for prostate cancer diagnostics.Nature cancer · 2025Article
- The Effectiveness and Harms of PSA-Based Prostate Cancer Screening: A Systematic Review.Healthcare (Basel, Switzerland) · 2025Review
- Implementing mHealth Apps Through Community Engagement to Promote Cancer Screening: A Scoping Review.Healthcare (Basel, Switzerland) · 2025Review
- Sociodemographic disparities in incidence rates of advanced and low-risk prostate cancer as a proxy for diagnostic activity.Acta oncologica (Stockholm, Sweden) · 2025Article
- Diagnostic value of miR‑21 and miR‑221 as potential biomarkers for early diagnosis of prostate cancer.Molecular and clinical oncology · 2025Article
- Utilization of artificial intelligence in prostate cancer detection: a comprehensive review of innovations in screening and diagnosis.Frontiers in immunology · 2025Review
- Understanding prostate cancer care: recent progress and future direction.BMJ oncology · 2025Article
- Article
- Prostate Cancer Screening in Young Men.Journal of personalized medicine · 2024Review
- Understanding the Barriers to Prostate Cancer Population-Based Early Detection Programs: The PRAISE-U BEST Survey.Journal of personalized medicine · 2024Article
- Health Policy for Prostate Cancer Early Detection in the European Union and the Impact of Opportunistic Screening: PRAISE-U Consortium.Journal of personalized medicine · 2024Review
- Navigating through the Controversies and Emerging Paradigms in Early Detection of Prostate Cancer: Bridging the Gap from Classic RCTs to Modern Population-Based Pilot Programs.Journal of personalized medicine · 2023Article
- Can PSA testing become appropriate public health policy?BMJ oncology · 2023Article
- Evaluating a Prostate Cancer Education and Navigation to Screening Program for Black Men in South Carolina, U.S.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long-term screening with serum prostate-specific antigen (PSA) and systematic prostate biopsies can reduce prostate cancer mortality but leads to unacceptable overdiagnosis. Over the past decade, diagnostic methods have improved and the indolent nature of low-grade prostate cancer has been established. These advances now enable more selective detection of potentially lethal prostate cancer. This non-systematic review summarises relevant diagnostic advances, previous and ongoing screening trials, healthcare policies and important remaining knowledge gaps. Evidence synthesis and conclusions: The strong association between low serum PSA values and minimal long-term risk of prostate cancer death allows for adjusting screening intervals. Use of risk calculators, biomarkers and MRI to select men with a raised PSA value for biopsy and lesion-targeting rather than systematic prostate biopsies reduce the detection of low-grade cancer and thereby overdiagnosis. These improvements recently led the European Union to recommend its member states to evaluate the feasibility and effectiveness of organised screening programmes for prostate cancer. Nonetheless, important knowledge gaps remain such as the performance of modern diagnostic methods in long-term screening programmes and their impact on mortality. The knowledge gaps are currently being addressed in three large randomised screening trials. Population-based pilot programmes will contribute critical practical experience.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.